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Survival in XDR TB: Shifting the Curve and Shifting the
Paradigm
Neil A. Martinson, MBBCh MPH1,2 and Richard E. Chaisson, MD1
1Johns Hopkins University Center for TB Research, Baltimore, MD
2Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
The article by Kvasnovsky and colleagues in this issue of JAIDS describing the dismal
treatment outcomes of patients with extensively drug resistant tuberculosis (TB) in the
Eastern Cape of South Africa1 - a setting with a high prevalence of HIV and an extremely
high TB burden – is a ghastly reminder of the toll exacted by this explosive public health
crisis. Multidrug resistant (MDR) and extensively drug resistant (XDR) TB have derailed
the relatively few gains made in TB control in areas such as South Africa with high HIV
prevalence. It is no surprise that South Africa, with its high incidence of active TB (almost
1% of South Africa’s 50 million people were diagnosed with TB in 2009 2) and its
historically high rates of poor treatment outcomes, should also have a large number of
individuals with drug resistant TB. Drug-resistant Mycobacterium tuberculosis does not
exist in nature – it is the product of human intervention, selected by inappropriate or
inadequate treatment and poor adherence. XDR TB - MDR TB that has acquired resistance
to second line drugs for TB including the fluoroquinolones and at least one so-called
injectable agent - is the product of mismanagement of MDR TB. In South Africa, the
mistakes of the past are amplified by the large number of people rendered profoundly
susceptible to TB by HIV infection, compounded by ongoing weaknesses in TB control. A
significant proportion of individuals with MDR and XDR TB have never had exposure to
the selective pressure of TB treatment and appear likely to have been initially infected with a
resistant strain 3, 4. When drug-resistant TB develops, delays in diagnosis and initiation of
appropriate treatment exacerbate an already terrible situation by amplification of resistance,
ongoing transmission of infection in the community (and health institutions), and rapid
progression of disease to death.
The paper by Kvasnovsky and coworkers highlights several important challenges in
responding to drug-resistant TB. Firstly, the prognosis of patients with XDR is extremely
poor, irrespective of HIV serostatus; one quarter of the XDR TB patients reported in this
study died before they received any treatment for XDR, and many of these are likely to have
been co-infected with HIV. HIV-seronegative patients comprised a large proportion (45%)
of those who survived to receive MDR TB therapy, but over half had died within 2 years of
diagnosis. HIV-infected patients treated for XDR TB who did not receive antiretroviral
therapy (ART) had extremely poor survival, with only a third surviving to one year. As a
comparison, Harries et al reported that 23% of patients with all forms of TB died during TB
treatment in Malawi in 1997 5. Those fortunate enough to have been started on antiretroviral
Corresponding author: Dr. Neil Martinson, Center for Tuberculosis Research, Johns Hopkins University, Baltimore, MD USA.
neil1.martinson@gmail.com.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2012 June 1.
Published in final edited form as:













therapy (ART) in the current study had a similar survival to HIV-seronegative XDR
patients, but this should be viewed as “equally bad” rather than “equally good.” Two
landmark trials comparing optimal timing of ART initiation in relation to TB therapy in
HIV-infected adults have clearly shown that early initiation of ART reduces mortality – an
effect apparent at both high and low CD4 counts 6, 7. Differences in prognosis by HIV
serostatus and antiretroviral therapy reported here are similar to a larger retrospective report
from four treatment centers in South Africa 8 (which appear to include at least some of the
patients in the Kvasnovsky article). The survival data reported here – particularly the pre-
XDR-treatment mortality rate - are better than those in the report which sounded the initial
alarm of the potential threat of XDR to HIV-infected adults. Gandhi et al 3 described short-
term outcomes in patients diagnosed at a general hospital in the KwaZulu Natal, Province –
neighboring the Eastern Cape Province- about two years prior to those in this paper. The
authors reported that 52 of 53 XDR patients in their study died, 70% within a month of the
diagnostic specimen being taken and that all who were HIV-tested were HIV-seropositive.
In both settings mortality is unacceptably high, underscoring the urgent need for new
approaches to managing MDR and XDR TB.
New drugs and new regimens of drug combinations are desperately needed to treat drug-
resistant TB. The recent publication of a randomized trial of the novel ATP synthase
inhibitor TMC207 in MDR TB patients was an important step forward 9. Testing of this and
other novel TB agents should include both HIV-infected individuals and children if these
products are to be used in these populations. Successful regimens for drug-resistant TB
require a variety of drugs. They will likely include: new agents, such as TMC 207,
OPC-6768310 and PA-82411; re-purposed drugs, such as respiratory fluoroquinolones; and
optimized old drugs, including isoniazid and pyrazinamide. Although the world waits in
eager anticipation of the novel agents, existing agents are not being optimally used or may
be misused. For example, it is abundantly clear that moxifloxacin is a potent
fluoroquinolone 12 – more so than ofloxacin 13 - but many programs continue to use
ofloxacin because it is less expensive, contributing to treatment failure and the selection of
fluoroquinolone-resistant organisms. In addition, there is reason to believe that high-dose
isoniazid may be effective in treating organisms with mutations in the inhA gene14 and this
could improve and shorten regimens for MDR and XDR TB.
Secondly, the authors highlight delays in diagnosis of XDR TB; patients in this retrospective
cohort had a mean of 15.7 months of TB treatment prior to XDR diagnosis and cohort entry.
Delays in the clinical triggers to suspect and investigate drug resistant TB, which could be
fatal, are compounded by the built-in tardiness of culture-based drug sensitivity testing for
first and then second line TB drugs. The line probe assay (Genotype MTBDRplus®) which
has been made available in several high through-put laboratories in South Africa offers some
hope of overcoming lengthy delays in diagnosis of MDR TB and also rapidly confirms
infection with M. tuberculosis15. Unfortunately, its usefulness is restricted to smear positive
cases, thereby excluding most HIV-infected individuals with TB, who are likely to be smear
negative. The recently described Xpert MTB/RIF® real time polymerase chain reaction
(PCR) assay has enormous potential to identify both M. tuberculosis infection and genotypic
rifampin resistance 16, but expense may limit widespread implementation.
A further issue that complicates management of TB treatment is the possibility of re-
infection with another M. tuberculosis strain during and after treatment, quite possibly in the
clinics or hospitals where patients are receiving their MDR or XDR TB therapy. Although
confining patients in sanatoria may prevent spread of resistant TB in the community, the risk
of transmission is likely still present, not only between patients but also to health workers
who appear to be at higher risk of being admitted to hospital with XDR TB than the
populations they serve 17.
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Finally, reports such as the one in this issue, of programmatic outcomes, are bedeviled by
their retrospective and incomplete nature and describe only a subset of patients who not only
survive long delays prior to being diagnosed with MDR or XDR TB, but then have to reach
specialist public sector treatment programs which are often long distances from their homes.
Highlighting this diagnostic gap is a post mortem biopsy study with mycobacterial culture
and drug sensitivity testing conducted at a hospital in KwaZulu Natal that showed 17% of
cadavers dying from “natural” causes were infected with MDR TB; only one was on MDR
treatment prior to death 18. There is clearly a pressing need for much improved surveillance
of all forms of TB in high-burden countries, including all diagnosed cases, deaths as well as
treated patients. Currently, only patients who enroll in DOTS programs are reported in many
high-incidence countries, excluding mortality statistics to monitor and assess progress - or
the lack thereof.
Important public health and epidemiological lessons have been learnt from the XDR TB
epidemic. However, research and control efforts must continue to address all forms of TB,
including the approximately 93% of patients who do not have drug-resistant TB. Earlier
identification of cases of TB by active case finding 19, 20 together with rapid, routine drug
sensitivity testing, coupled with preventive treatment for those without evidence of active
TB, efforts to improve treatment adherence, and implementation of infection control
measures will reduce incidence of both drug susceptible and drug-resistant TB.
Retrospective studies such as this one provide a critical baseline from which progress can be
measured, but prospective and complete epidemiologic surveillance, including molecular
epidemiology, is crucially important to monitor, respond to and overcome the TB pandemic.
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